Javier Sánchez‐Arráez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Javier Sánchez‐Arráez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Abril‐Pérez
Dermatology Department Hospital Universitario y Politécnico la Fe València Spain
5 shared publications - Ignacio Torres-Navarro
Department of Dermatology Hospital Universitario y Politécnico La Fe Valencia Spain
5 shared publications - Juncal Roca Ginés
Dermatology Department Hospital Universitario y Politécnico la Fe València Spain
3 shared publications - Rodolfo David Palacios-Diaz
Department of Dermatology La Fe University and Polytechnic Hospital Valencia Spain
2 shared publications - Altea Esteve Martínez
Department of Dermatology, General University Hospital of Valencia, Valencia, Spain
1 shared publication Ana Facal‐Malvar
Hematology Department Hospital Universitari i Politècnic La Fe Valencia Spain
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (12) , 3757-3764
Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort
Introduction Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients’ quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. This study evaluated the efficacy and safety of tralokinumab in adolescent patients, with a particular focus on identifying which patient profiles may derive the greatest benefit from this therapy. Methods A retrospective multicenter study was conducted across nine Spanish hospitals, including patients from 12 to 17 years old with moderate-to-severe AD treated with tralokinumab. Results A total of 27 patients were included, with a mean age of 14.8 years. Nine had previously received treatment with dupilumab, five due to primary or secondary failure, and four due to adverse events. One patient had been treated with upadacitinib, which was discontinued because of primary failure and acne. A statistically significant reduction was achieved in Eczema Area and Severity Index (EASI), pruritus visual analog scale (VAS), and Investigator’s Global Assessment (IGA) scores. Palmoplantar involvement was observed in 44.4% of patients; after 24 weeks of treatment, 83.3% of those with palmoplantar involvement experienced complete resolution. Additionally, 37.0% of patients were overweight or obese, with no statistically significant differences in treatment efficacy. Conclusion Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12–17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.
- 23 September 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (12) , 3757-3764
Open AccessLong-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort
Introduction Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients’ quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. This study evaluated the efficacy and safety of tralokinumab in adolescent patients, with a particular focus on identifying which patient profiles may derive the greatest benefit from this therapy. Methods A retrospective multicenter study was conducted across nine Spanish hospitals, including patients from 12 to 17 years old with moderate-to-severe AD treated with tralokinumab. Results A total of 27 patients were included, with a mean age of 14.8 years. Nine had previously received treatment with dupilumab, five due to primary or secondary failure, and four due to adverse events. One patient had been treated with upadacitinib, which was discontinued because of primary failure and acne. A statistically significant reduction was achieved in Eczema Area and Severity Index (EASI), pruritus visual analog scale (VAS), and Investigator’s Global Assessment (IGA) scores. Palmoplantar involvement was observed in 44.4% of patients; after 24 weeks of treatment, 83.3% of those with palmoplantar involvement experienced complete resolution. Additionally, 37.0% of patients were overweight or obese, with no statistically significant differences in treatment efficacy. Conclusion Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12–17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.
- 18 October 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (3) , E191-E193
Foreign body reaction to silicone after hematopoietic stem cell transplantation
- 18 October 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (3) , E191-E193
Foreign body reaction to silicone after hematopoietic stem cell transplantation
- Open Access
- 22 April 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2355
Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital
Multiple primary melanomas (MPM) refer to the occurrence of more than one synchronous or metachronous melanoma in the same individual. The aim of this study was to identify the frequency of MPM and describe the clinical and histopathologic characteristics of patients with MPM. An observational single-center retrospective study was designed based on a cohort of melanoma patients followed in a tertiary care hospital. Fifty-eight (8.9%) patients developed MPM. Most patients were men (65.5%) and the median age at the time of diagnosis of the first melanoma was 71 years old. The median time of diagnosis of the second melanoma from the first melanoma was 10.9 months, and 77.6% of second melanomas were diagnosed within the first 5 years. In total, 29 (50%) and 28 (48.3%) first and second melanomas were located in the trunk, respectively. Concordance of anatomic site between primary and subsequent melanoma was found in 46.6% of the patients. Proportion of in situ melanomas was increasingly higher in subsequent melanomas (from 36.21% of first melanomas to 100% of fifth melanomas). An increasing rate of melanomas with histological regression was observed within subsequent melanomas (from 60.3% of first melanomas to 80% of third melanomas). Our results support the importance of careful long-term follow-up with total body examination in melanoma patients.
- 22 April 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2355
Open AccessMultiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital
Multiple primary melanomas (MPM) refer to the occurrence of more than one synchronous or metachronous melanoma in the same individual. The aim of this study was to identify the frequency of MPM and describe the clinical and histopathologic characteristics of patients with MPM. An observational single-center retrospective study was designed based on a cohort of melanoma patients followed in a tertiary care hospital. Fifty-eight (8.9%) patients developed MPM. Most patients were men (65.5%) and the median age at the time of diagnosis of the first melanoma was 71 years old. The median time of diagnosis of the second melanoma from the first melanoma was 10.9 months, and 77.6% of second melanomas were diagnosed within the first 5 years. In total, 29 (50%) and 28 (48.3%) first and second melanomas were located in the trunk, respectively. Concordance of anatomic site between primary and subsequent melanoma was found in 46.6% of the patients. Proportion of in situ melanomas was increasingly higher in subsequent melanomas (from 36.21% of first melanomas to 100% of fifth melanomas). An increasing rate of melanomas with histological regression was observed within subsequent melanomas (from 60.3% of first melanomas to 80% of third melanomas). Our results support the importance of careful long-term follow-up with total body examination in melanoma patients.
- Open Access
- 1 October 2020
- Published by Elsevier in Anales de Pediatría
- Vol. 93 (4) , 276-277
Respuesta al comentario sobre «Perniosis del confinamiento, una vieja conocida en el contexto del COVID-19»
- 1 October 2020
- Published by Elsevier in Anales de Pediatría
- Vol. 93 (4) , 276-277
Open AccessRespuesta al comentario sobre «Perniosis del confinamiento, una vieja conocida en el contexto del COVID-19»
- Open Access
- 26 May 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (10) , E537-E539
A case of cefditoren‐induced acute generalized exanthematous pustulosis during COVID‐19 pandemics. Severe cutaneous adverse reactions are an issue
We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID‐19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.
- 26 May 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (10) , E537-E539
Open AccessA case of cefditoren‐induced acute generalized exanthematous pustulosis during COVID‐19 pandemics. Severe cutaneous adverse reactions are an issue
We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID‐19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.